Trial Profile

A Phase 1, First in human clinical trial assessing safety and pharmacokinetics of GT02287 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GT-02287 (Primary)
Indications Parkinson's disease
Focus Adverse reactions; First in man
Sponsors Gain Therapeutics

Most Recent Events

30 Apr 2025 According to a Gain Therapeutics media release, company announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY.
06 Feb 2025 Status changed to completed.
14 Nov 2024 According to a Gain Therapeutics media release, the company expects the initiation of Phase 1b Study of GT-02287 in Parkinson's patients by end of 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com